shopping cart Your cart is empty
  • Home
  • Pharmaceutical
  • Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug Type (Oral Contraceptive, Ovulation Inducing Agents, Facial Hair Gr...

Polycystic Ovarian Syndrome (PCOS) Therapeutics Market By Drug Type (Oral Contraceptive, Ovulation Inducing Agents, Facial Hair Growth Inhibitor, Insulin Sensitizing Agent) - Growth, Future Prospects & Competitive Analysis, 2017- 2025

Published By: Brisk Insights | Published On: Oct 28, 2021

 

Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. Polycystic ovarian syndrome (PCOS) therapeutics market is rapidly growing due to factors such as growing prevalence, changing lifestyle pattern, early diagnosis and significant unmet needs.

 

The report titled “Polycystic ovarian syndrome (PCOS) therapeutics Market - Growth, Future Prospects and Competitive Analysis, 2017–2025” offers strategic insights into the overall PCOS therapeutics market along with the market size and estimates for the duration 2015 to 2025. The research study covers in-depth analysis of market segments based on drug type and different geographical regions. Geographically, the global PCOS therapeutics market is studied for the following regional markets: 

 

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of LATAM
  • Middle East and Africa
    • GCC
    • Rest of MEA

 

Market size and forecast for these regional and country level markets are presented in this study for the period 2015-2025. Market growth rates for the forecast period 2017-2025 are also included in this report, considering 2016 as the base year.

 

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global polycystic ovarian syndrome (PCOS) therapeutics market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global polycystic ovarian syndrome (PCOS) therapeutics market. This report concludes with company profiles section that highlights major information about the key players engaged in global polycystic ovarian syndrome (PCOS) therapeutics market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.

    

Thus, the research study provides a holistic view of the global polycystic ovarian syndrome (PCOS) therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.

 

Based on drug type, the global polycystic ovarian syndrome (PCOS) therapeutics market is segmented as follows:  

 

  • Oral Contraceptive
  • Ovulation Inducing Agents
  • Facial Hair Growth Inhibitor
  • Insulin Sensitizing Agent
  • Other

 

Polycystic ovary syndrome (PCOS) is a hormonal disorder affecting approximately 10 percent of women of reproductive age. Women with PCOS may have infrequent or menstrual periods or excess male hormone levels. There is no cure for PCOS but treatment focuses on managing symptoms, such as infertility, hirsutism, acne or obesity. Change in lifestyle, increase in prevalence of PCOS and rising treatment awareness are prime factors that drive the growth of PCOS therapeutics market globally. For the purpose of the study PCOS therapeutics market is segmented on the basis of drug type such as oral contraceptive, ovulation inducing agents, facial hair growth inhibitor, insulin sensitizing agent and other therapeutics. Currently, oral contraceptive is the major revenue contributor because it is preferred as first line treatment option. Oral contraceptives are effective to regulate PCOS symptoms such as reduction of extra hair growth, lower risks for endometrial cancer, ovarian cancer, and ovarian cysts, cleansing the skin and to regulate the periods.

 

For the purpose of this study, the global polycystic ovarian syndrome (PCOS) therapeutics market is categorized into:

 

  • North America
  • Europe
  • Asia Pacific
  • Latin America (LATAM)
  • Middle East and Africa (MEA)

 

According to national institutes of health (NIH), PCOS affects 8 to 20 percent of reproductive age women worldwide. In the base year 2016, North America dominated the polycystic ovarian syndrome (PCOS) therapeutics market. United States was largest revenue contributor due to the higher number of targeted population, higher cost of therapeutics, lifestyle pattern and higher treatment awareness among the general population. According to national institutes of health (NIH), PCOS affects more than 5 percent of women in the United States. On the other hand, rapid evolution of healthcare infrastructure, increasing number of target population, growing treatment awareness among the general population and increasing penetration of major market players will lead to Asia Pacific witnessing the fastest growth rate.

 

Chapter 1 Preface


1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I – Secondary Research
1.3.2 Phase II – Primary Research
1.3.3 Phase III – Expert Panel Review
1.3.4 Assumptions

 

Chapter 2 Executive Summary


2.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Snapshot
2.2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type
2.3 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share, by Geography, 2016 (Value %)

 

Chapter 3 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Analysis


3.1 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Attractive Investment Proposition
3.4 Competitive Landscape of Key Players in Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
3.5 Top 3 Countries

 

Chapter 4 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type


4.1 Overview
4.2 Attractive Investment Proposition: Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type
4.3 Oral Contraceptive
4.4 Ovulation Inducing Agents
4.5 Facial Hair Growth Inhibitor
4.6 Insulin Sensitizing Agent
4.7 Other Drugs

 

Chapter 5 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, By Geography


5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015- 2025 (US$)
5.2.2 North America Polycystic Ovarian Syndrome (PCOS) Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015- 2025 (US$)
5.3.2 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015- 2025 (US$)
5.5.2 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015- 2025 (US$)

 

Chapter 6 Company Profiles


6.1 Bristol Myers Squibb
6.2 Crinetics Pharmaceuticals, Inc.
6.3 EffRx, Inc.
6.4 Ferring Pharmaceuticals
6.5 Merck KGaA
6.6 Neurocrine Biosciences, Inc.
6.7 Novartis Pharmaceuticals
6.8 Pfizer Inc.
6.9 Sanofi Aventis
6.10 Teva Pharmaceutical Industries Limited

TABLE 1 Market Positioning of Key Players in Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
TABLE 2 Top 3 Countries in Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market
TABLE 3 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015 – 2025 (US$ Mn)
TABLE 4 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Geography, 2015 – 2025 (US$ Mn)
TABLE 5 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 6 North America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 7 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 8 Europe Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 9 Asia Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 10 Asia Pacific Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 11 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 12 Latin America Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 13 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2015-2025 (US$ Mn)
TABLE 14 Middle East and Africa Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Country, 2015 – 2025 (US$ Mn)
TABLE 15 Bristol Myers Squibb: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 16 Crinetics Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 17 EffRx, Inc.,: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 18 Ferring Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 19 Merck KGaA: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 20 Neurocrine Biosciences, Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 21 Novartis Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 22 Pfizer Inc.: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 23 Sanofi Aventis: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)
TABLE 24 Teva Pharmaceutical Industries Limited: Company Snapshot (Business Description; Financial Information; Product Position/Portfolio; News Coverage)

FIG. 1 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market: Research Methodology
FIG. 2 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2016 (US$ Mn)
FIG. 3 Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market Share, by Geography, 2016 (Value %)
FIG. 4 Attractive Investment Proposition: Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Geography, 2016
FIG. 5 Attractive Investment Proposition: Global Polycystic Ovarian Syndrome (PCOS) Therapeutics Market, by Drug Type, 2016
FIG. 6 Global Oral Contraceptive Market, 2015 – 2025 (US$ Mn)
FIG. 7 Global Ovulation Inducing Agents Market, 2015 – 2025 (US$ Mn)
FIG. 8 Global Facial Hair Growth Inhibitor Market, 2015 – 2025 (US$ Mn)
FIG. 9 Global Insulin Sensitizing Agent Market, 2015 – 2025 (US$ Mn)
FIG. 10 Global Other Drugs Market, 2015 – 2025 (US$ Mn)

Choose License


Contact Information

: 24/7 Research Support

: sales@briskinsights.com

: +448081890034 (UK)